Genmab Announces Financial Results for the First Quarter 2012 - msnbc.com

Arzerra(r) net sales increased 32% over Q1 2011 New Drug Application for ofatumumab submitted in Japan Amended protocol for ofatumumab Phase III head to head study vs rituximab in DLBCL; moved estimated primary data readout forward Improved ...

DGAP-News: Genmab Announces Financial Results for the First Quarter 2012 - finanztreff

We have achieved a number of business milestones during the last months including the filing of the New Drug Application (NDA) in Japan for ofatumumab and another milestone in our Lundbeck collaboration. We also continue to focus on resources and in the ...

Genmab A/S : Milestone Triggered in Connection with Filing of New Drug Application in Japan for Arzerra - 4-traders (press release)

The NDA is for Arzerra® (ofatumumab) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy. Today's announcement does not affect Genmab's financial guidance for 2012. About Genmab A/S Genmab is a publicly ...

Genmab A/S : Daratumumab Clinical Data to Be Presented at ASCO and EHA - 4-traders (press release)

In addition, several other ofatumumab and daratumumab abstracts will be presented at the ASCO and EHA conferences. Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL - Abstract #6584 Poster presentation June 4 at 1:15PM ...

MorphoSys to Present MOR208 Preclinical Combination Therapy Data at ASCO Meeting - Market Wire

The issuer is solely responsible for the content of this announcement. Synergistic Effects Seen with Four Approved Treatment Options Including Rituximab and Ofatumumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced promising pre ...

Milestone Triggered in Connection With Filing of New Drug Application in Japan for Arzerra - MENAFN

Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(R)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated ...

Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual … - Yahoo Finance

Byrd et al., The Ohio State University, Columbus, Ohio. Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma ...

Blood Cancers: What to Look for in Leukemia - Medscape News

The final abstract [6] I am going to mention involves the same agent but in combination with the anti-CD20 ofatumumab in relapse-refractory CLL. In a small number of patients treated with this combination, the response rate was 100%, including a number of ...

Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent Developments - Yahoo Finance

The two oral presentations will highlight the first reporting on data from the ibrutinib (formerly PCI-32765) Phase II CLL single agent trial in treatment naïve patients and the ibrutinib Phase Ib/II CLL combination trial with ofatumumab in ...

United States: GSK And Genentech Settle Cabilly Patent Lawsuit - Mondaq

In the lawsuit, started in October 2009, GSK had sought a declaration that the Cabilly II / III patents were invalid, unenforceable and not infringed by the manufacture, use, sale, offer to sell or importation of GSK's ofatumumab (ARZERRA) antibody product.